Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Physical interaction and functional antagonism between the RNA polymerase II elongation factor ELL and p53.

Shinobu N, Maeda T, Aso T, Ito T, Kondo T, Koike K, Hatakeyama M.

J Biol Chem. 1999 Jun 11;274(24):17003-10.

3.

An RNA polymerase II elongation factor encoded by the human ELL gene.

Shilatifard A, Lane WS, Jackson KW, Conaway RC, Conaway JW.

Science. 1996 Mar 29;271(5257):1873-6.

PMID:
8596958
5.

Transcriptional inhibition of p53 by the MLL/MEN chimeric protein found in myeloid leukemia.

Maki K, Mitani K, Yamagata T, Kurokawa M, Kanda Y, Yazaki Y, Hirai H.

Blood. 1999 May 15;93(10):3216-24.

6.

A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL.

DiMartino JF, Miller T, Ayton PM, Landewe T, Hess JL, Cleary ML, Shilatifard A.

Blood. 2000 Dec 1;96(12):3887-93.

7.
8.

Cloning and characterization of the EAP30 subunit of the ELL complex that confers derepression of transcription by RNA polymerase II.

Schmidt AE, Miller T, Schmidt SL, Shiekhattar R, Shilatifard A.

J Biol Chem. 1999 Jul 30;274(31):21981-5.

9.

The elongation factor ELL (eleven-nineteen lysine-rich leukemia) is a selective coregulator for steroid receptor functions.

Pascual-Le Tallec L, Simone F, Viengchareun S, Meduri G, Thirman MJ, Lomb├Ęs M.

Mol Endocrinol. 2005 May;19(5):1158-69. Epub 2005 Jan 13.

PMID:
15650021
10.

Transcription factors TFIIF, ELL, and Elongin negatively regulate SII-induced nascent transcript cleavage by non-arrested RNA polymerase II elongation intermediates.

Elmendorf BJ, Shilatifard A, Yan Q, Conaway JW, Conaway RC.

J Biol Chem. 2001 Jun 22;276(25):23109-14. Epub 2001 Mar 19.

11.

The elongation domain of ELL is dispensable but its ELL-associated factor 1 interaction domain is essential for MLL-ELL-induced leukemogenesis.

Luo RT, Lavau C, Du C, Simone F, Polak PE, Kawamata S, Thirman MJ.

Mol Cell Biol. 2001 Aug;21(16):5678-87.

12.

ELL-associated factor 2 (EAF2), a functional homolog of EAF1 with alternative ELL binding properties.

Simone F, Luo RT, Polak PE, Kaberlein JJ, Thirman MJ.

Blood. 2003 Mar 15;101(6):2355-62. Epub 2002 Nov 21.

13.
14.

EAF1, a novel ELL-associated factor that is delocalized by expression of the MLL-ELL fusion protein.

Simone F, Polak PE, Kaberlein JJ, Luo RT, Levitan DA, Thirman MJ.

Blood. 2001 Jul 1;98(1):201-9.

15.

Identification and Characterization of a Schizosaccharomyces pombe RNA Polymerase II Elongation Factor with Similarity to the Metazoan Transcription Factor ELL.

Banks CA, Kong SE, Spahr H, Florens L, Martin-Brown S, Washburn MP, Conaway JW, Mushegian A, Conaway RC.

J Biol Chem. 2007 Feb 23;282(8):5761-9. Epub 2006 Dec 6.

16.

Functional analysis of the leukemia protein ELL: evidence for a role in the regulation of cell growth and survival.

Johnstone RW, Gerber M, Landewe T, Tollefson A, Wold WS, Shilatifard A.

Mol Cell Biol. 2001 Mar;21(5):1672-81.

17.

Nonredundant roles of the elongation factor MEN in postimplantation development.

Mitani K, Yamagata T, Iida C, Oda H, Maki K, Ichikawa M, Asai T, Honda H, Kurokawa M, Hirai H.

Biochem Biophys Res Commun. 2000 Dec 20;279(2):563-7.

PMID:
11118326
18.

ELL binding regulates U19/Eaf2 intracellular localization, stability, and transactivation.

Xiao W, Jiang F, Wang Z.

Prostate. 2006 Jan 1;66(1):1-12.

PMID:
16114057
19.

A novel variant form of MLL-ELL fusion transcript with t(11;19)(q23;p13.1) in chronic myelomonocytic leukemia transforming to acute myeloid leukemia.

Kakihana K, Kubo F, Wakabayashi S, Kurosu T, Miki T, Murakami N, Miura O.

Cancer Genet Cytogenet. 2008 Jul 15;184(2):109-12. doi: 10.1016/j.cancergencyto.2008.04.001.

PMID:
18617060
20.

Supplemental Content

Support Center